Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NSE India Stock Exchange  >  Biocon Limited    BIOCON   INE376G01013

BIOCON LIMITED

(BIOCON)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Nse India Stock Exchange
02/14/2020 02/17/2020 02/18/2020 02/19/2020 02/20/2020 Date
307.8(c) 303.15(c) 300.65(c) 306.1(c) 315.05(c) Last
2 119 124 3 201 093 3 625 458 2 287 640 6 990 659 Volume
+0.24% -1.51% -0.82% +1.81% +2.92% Change
More quotes
Financials (INR)
Sales 2020 67 156 M
EBIT 2020 12 909 M
Net income 2020 8 864 M
Debt 2020 16 584 M
Yield 2020 0,39%
Sales 2021 82 125 M
EBIT 2021 17 470 M
Net income 2021 11 989 M
Debt 2021 18 587 M
Yield 2021 0,45%
P/E ratio 2020 42,1x
P/E ratio 2021 31,3x
EV / Sales2020 5,80x
EV / Sales2021 4,76x
Capitalization 373 B
More Financials
Company
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the... 
More about the company
Surperformance© ratings of Biocon Limited
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOCON LIMITED
01/27BIOCON : API Manufacturing Facility Completes Pre-Approval and GMP U.S. FDA insp..
AQ
01/24BIOCON : Q3FY20 Earnings - Revenue at Rs 1,784 Cr, Up 14% EBITDA at Rs 480 Cr, U..
AQ
01/20BIOCON : Oral Solid Dosage Manufacturing Facility Completes Pre-Approval U.S. FD..
AQ
01/20BIOCON LIMITED : quaterly earnings release
2019BIOCON : and Equillium Expand Exclusive Licensing Agreement for Itolizumab to In..
AQ
2019BIOCON : Biologics Symposium on '100 years of Insulin Delivering on Universal Ac..
AQ
2019BIOCON : Biologics Takes Forward Its Mission to Unlock Universal Access to Insul..
AQ
2019BIOCON : Siddharth Mittal Takes Over as CEO and Joint Managing Director of Bioco..
AQ
2019BIOCON : Mylan and Biocon Launch Trastuzumab Biosimilar, Ogivri, in the U.S.
AQ
2019BIOCON : USFDA Approves Biocon's sBLA for Pegfilgrastim New Manufacturing Facili..
AQ
2019BIOCON : Moves Up to Rank No. 6 on Science Careers' Top 20 Global Pharma & Biote..
AQ
2019EVOTEC : Just Evotec Biologics and Biocon Biologics sign licensing deal for a bi..
AQ
2019BIOCON : and Mylan Launch First Insulin Glargine Biosimilar, Semglee, in Austral..
AQ
2019BIOCON : Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin b..
AQ
2019BIOCON : Biologics Expands its R&D Footprint through Acquisition
AQ
More news
News in other languages on BIOCON LIMITED
01/20BIOCON LIMITED : Veröffentlichung des Quartalsergebnisses
01/20BIOCON LIMITED : publication des résultats trimestriels
2019La FDA homologue des génériques de Gilenya de Novartis
2019FDA erteilt Zulassungen für Generika zum Novartis-Medikament Gilenya
2019BIOCON LTD : Ex-dividend day for final dividend
More news
Analyst Recommendations on BIOCON LIMITED
More recommendations
Sector news : Bio Therapeutic Drugs
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Bio Therapeutic Drugs
Chart BIOCON LIMITED
Duration : Period :
Biocon Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCON LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 313,11  INR
Last Close Price 315,05  INR
Spread / Highest target 19,7%
Spread / Average Target -0,62%
Spread / Lowest Target -36,5%
EPS Revisions
Managers
NameTitle
Kiran Mazumdar-Shaw Executive Chairman & Joint Managing Director
Siddharth Mittal Chief Executive Officer & Joint Managing Director
John McCallum Marshall Shaw Vice Chairman
Ravi Rasandra Mazumdar Non-Independent Non-Executive Director
Daniel Mark Bradbury Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOCON LIMITED7.27%5 188
GILEAD SCIENCES7.26%88 181
VERTEX PHARMACEUTICALS12.49%63 855
REGENERON PHARMACEUTICALS7.37%43 886
WUXI APPTEC CO., LTD.22.35%26 379
GENMAB A/S15.09%16 125